Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Andexanet alfa versus usual care for factor Xa inhibitor-associated acute intracranial hemorrhage
NL-OMON49173Phase 4Recruiting
- Sponsor
- Portola Pharmaceuticals
- Start
- Nov 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of andexanet alfa in intracerebral hemorrhage (ICH) (2 arms), sponsored by Portola Pharmaceuticals. Primary endpoint: Effective hemostasis. Started Nov 2019; status: recruiting.
02
Drugs
andexanet alfa
03
Conditions
intracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on NL-OMON49173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49173.